Alphamab Oncology announces HK$20m share repurchase plan

Alphamab Oncology announced a voluntary on-market share repurchase plan of up to HK$20 million. The board of directors resolved to repurchase ordinary shares pursuant to a general mandate approved by shareholders on June 12, 2025. This mandate remains effective until the conclusion of the next annual general meeting, the expiration of the period for the next annual general meeting, or its revocation by shareholders. The repurchases will comply with relevant listing rules and company regulations.

The company intends to fund the repurchases using its existing available cash. Repurchase prices will not exceed 5% or more than the average closing price over the five trading days preceding the repurchase date. Repurchased shares may either be cancelled or held as treasury shares, depending on market conditions and capital management needs.

The board believes the current trading price does not reflect the company's intrinsic value and that the repurchase will demonstrate confidence in its business outlook, ultimately benefiting shareholders. Alphamab Oncology stated that its financial resources are sufficient to support the program while maintaining a solid financial position. As of the announcement date, no shares have been repurchased under this mandate.